Literature DB >> 16407047

Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls?

John P Kavanagh1, Norbert Laube.   

Abstract

PURPOSE: The BRI has been shown to discriminate between calcium oxalate stone formers and controls. BRI is the ratio of the concentration of ionized calcium and the amount of oxalate that must be added to 200 ml urine to initiate crystallization. Higher BRI values are predictive of being a stone former and a value of 1.0 has been found to be the cutoff value to distinguish stone formers and controls. It is not easy to present a consistent argument based on the thermodynamics of calcium oxalate crystallization to account for the success of this index. For instance, why should 2 samples sharing the same BRI but with different ionized calcium and oxalate values have the same likelihood of being obtained from a stone former?
MATERIALS AND METHODS: Using data on 195 samples the distribution and interrelationships of measured variables were examined. They were used to calculate illustrative data with which it was possible to examine the effects of varying the parameters and their relationships.
RESULTS: Data simulations identified 3 necessary and sufficient conditions that must be met for BRI to be an effective discriminator between stone former and nonstone former urine samples.
CONCLUSIONS: The success of BRI can be explained as the natural outcome of there being significantly different distributions (stone formers vs nonstone formers) of the concentration of ionized calcium and the formation product minus activity product difference as well as the correlation between these 2 variables.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407047     DOI: 10.1016/S0022-5347(05)00145-X

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Urolithiasis--an interdisciplinary diagnostic, therapeutic and secondary preventive challenge.

Authors:  Christian Fisang; Ralf Anding; Stefan C Müller; Stefan Latz; Norbert Laube
Journal:  Dtsch Arztebl Int       Date:  2015-02-06       Impact factor: 5.594

2.  Kinetics of calcium oxalate crystal formation in urine.

Authors:  Norbert Laube; Florian Klein; Falk Bernsmann
Journal:  Urolithiasis       Date:  2016-06-21       Impact factor: 3.436

3.  Cats with Genetic Variants of AGXT2 Respond Differently to a Dietary Intervention Known to Reduce the Risk of Calcium Oxalate Stone Formation.

Authors:  Jean A Hall; Kiran S Panickar; Jeffrey A Brockman; Dennis E Jewell
Journal:  Genes (Basel)       Date:  2022-04-28       Impact factor: 4.141

4.  Temporary risk identification in urolithiasis.

Authors:  Y M Fazil Marickar; Abiya Salim
Journal:  Urol Res       Date:  2009-10-15

5.  A new approach to the diagnosis of children's urolithiasis based on the Bonn Risk Index.

Authors:  Tadeusz Porowski; Walentyna Zoch-Zwierz; Jerzy Konstantynowicz; Katarzyna Taranta-Janusz
Journal:  Pediatr Nephrol       Date:  2008-03-12       Impact factor: 3.714

6.  Relevance of the BONN Risk Index for metabolic monitoring of patients with calcium oxalate urolithiasis: a clinical application study of the Urolizer.

Authors:  Wolfgang Berg; Robin Bechler; Claudia Haas; Norbert Laube
Journal:  Urol Res       Date:  2009-02-10

7.  Normative data on the Bonn Risk Index for calcium oxalate crystallization in healthy children.

Authors:  Tadeusz Porowski; Walentyna Zoch-Zwierz; Anna Wasilewska; Anthony Spotyk; Jerzy Konstantynowicz
Journal:  Pediatr Nephrol       Date:  2007-01-10       Impact factor: 3.714

8.  Correlation of Osteoporosis and Calcium Urolithiasis in Adult Population.

Authors:  Radojka Bijelic; Snjezana Milicevic; Jagoda Balaban
Journal:  Med Arch       Date:  2016-01-31

9.  Increased dietary long-chain polyunsaturated fatty acids alter serum fatty acid concentrations and lower risk of urine stone formation in cats.

Authors:  Jean A Hall; Jeff A Brockman; Stephen J Davidson; Jen M MacLeay; Dennis E Jewell
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.